Literature DB >> 9003111

Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.

A M Moers1, R M Landsvater, C Schaap, J M Jansen-Schillhorn van Veen, I A de Valk, G H Blijham, J W Höppener, T M Vroom, H K van Amstel, C J Lips.   

Abstract

BACKGROUND: Multiple endocrine neoplasia type 2A (MEN 2A) is a hereditary syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism. Familial MTC (FMTC) is characterized by MTC only. Both MEN 2A and FMTC are caused by germline mutations of the RET proto-oncogene.
PURPOSE: To assess genotype/phenotype correlations, large families have to be examined periodically over a long period using an extensive screening program. PATIENTS AND METHODS: Since 1973, we screened a large family with hereditary C cell carcinoma for MTC, pheochromocytoma, and parathyroid disease by clinical tests and imaging methods. A germline codon Cys618 to Ser mutation in the RET proto-oncogene was recently identified in this family. The disease phenotype associated with this mutation was compared with that of Cys634 mutations in some other large MEN 2A families.
RESULTS: The distinct course of disease in the family described here is similar to that in other FMTC families and MEN 2A families with a Cys618 mutation of the RET gene, but clearly different from that in families with a Cys634 mutation. The frequency of pheochromocytomas and parathyroid disease is clearly lower, whereas cure rates and life expectancy are higher. However, in families with a Cys618 mutation, pheochromocytoma and parathyroid disease do occur.
CONCLUSION: In FMTC families with cysteine codon mutations of the RET proto-oncogene, screening for other endocrinopathies is mandatory, since these may not be MTC-only families. Therefore, we suggest that MEN 2A families should not be subclassified into MEN 2A and FMTC, but rather according to their specific mutation in the RET protein (i.e., for this family MEN 2A RET C618S).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9003111     DOI: 10.1016/s0002-9343(96)00330-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma -- only phenotype with incomplete penetrance: implications for screening and management of carrier status.

Authors:  Tabib Dabir; Steven J Hunter; Colin F J Russell; Damien McCall; Patrick J Morrison
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 4.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

Review 5.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

Review 6.  Sporadic and familial medullary thyroid carcinoma: state of the art.

Authors:  Tricia A Moo-Young; Amber L Traugott; Jeffrey F Moley
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

7.  A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation.

Authors:  Jinhyang Jung; Shinya Uchino; Youngha Lee; Hoyong Park
Journal:  J Korean Med Sci       Date:  2010-01-21       Impact factor: 2.153

8.  Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.

Authors:  Beatriz González-Yebra; María Elena Medrano; Alejandra Mantilla; Virginia Palma; Carmen Colin; Dulce María Hernández; José Tapia; Brian Dawson; Mauricio Salcedo
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

9.  A Case of medullary thyroid carcinoma with de novo V804M RET germline mutation.

Authors:  Young Sik Choi; Hye Jung Kwon; Bu Kyung Kim; Su Kyoung Kwon; Yo Han Park; Jeong Hoon Kim; Sang Bong Jung; Chang Hoon Lee; Seong Keun Lee; Shinya Uchino
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

Review 10.  Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.

Authors:  Rute Martins; Maria João Bugalho
Journal:  Int J Endocrinol       Date:  2014-05-12       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.